LG Chem
Biosimilar developer, South Korea. 2 development products across 2 molecules: insulin glargine, somatropin.
First approval in the Atlas: Aug 2002, L.G. Chemicals (LG Life Sciences) (INN only), somatropin (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved2
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Insulin glargine | LG Life Sciences insulin glargine | · | · | · | · | Dec 2011 | · |
| Somatropin | LG Life Sciences somatropin | · | · | · | · | Aug 2002 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOAug 2002L.G. Chemicals (LG Life Sciences) (INN only), somatropin
- CDSCODec 2011LG Life Sciences (INN only), insulin glargine
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.